· Published by Health Canada · Official notice
This is duplicated text of a letter from Hospira Healthcare Corporation. Contact the company for a copy of any references, attachments or enclosures.
September 17, 2012
Dear Health Care Professional
Subject: Product Recall for one lot of Propofol Injectable Emulsion 1%, 1g/100mL, (DIN: 02236887) due to the presence of particulate matter
Hospira Healthcare Corporation is bringing to your immediate attention, a recall of one lot of Propofol Injectable Emulsion 1%, 10mg/mL, lot 09029DJ (expiry date 2014/09/01), that was initiated on September 7, 2012. The recall has been initiated due to the presence of visible particles (metallic and elastomeric) identified in a propofol vial.
“Propofol is an intravenous hypnotic agent for use in the induction and maintenance of general anesthesia or sedation for inpatient and outpatient surgery. Propofol is also indicated for pediatric anesthesia in children 3 years of age or older. It may also be used for sedation during diagnostic procedures and should only be administered to intubated, mechanically ventilated patients in the Intensive Care Unit (ICU) to provide continuous sedation and control of stress responses."(CPM, Propofol injection 10mg/mL. December 3, 2004; page 6.)
This lot of Propofol was distributed to certain hospitals in December 2011.
Hospira has not received any reports of adverse events associated with Propofol Injectable Emulsion 1% (10mg/mL) from its customers. Hospira has initiated investigations to determine the root cause and corrective and preventive actions.
All hospitals who received the affected lot were individually contacted to initiate quarantine and return of the affected product. This communication is intended to raise health professional awareness regarding potential complications that may occur following the use of the affected Propofol Injectable Emulsion 1%, (1g/100mL) in order to monitor patients closely and treat them if needed.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected adverse reactions in patients receiving Propofol Injectable Emulsion 1% (1g/100mL) should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:
Hospira Healthcare Corporation
Complaint & Safety Department
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com
To correct your mailing address or fax number, contact Hospira Healthcare Corporation.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Health and Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
Sincerely,
original signed by
Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation